• Lead asset amsulostat continues to build momentum with new trials and regulatory milestones
• Pipeline assets SNT-4728 and SNT-9465 progress with key data expected in 2026
• Proforma cash balance of $12.3 million at 31 December 2025

Syntara Ltd, a clinical-stage drug development company, provided a quarterly update on its activities for the period ended 31 December 2025. The company's lead asset, amsulostat, continued to build momentum with new clinical trials and regulatory milestones. Syntara initiated the MDS05/D3 MESSAGE Phase 2 clinical trial in Australia to evaluate amsulostat in combination with the hypomethylating agent ASTX727 in patients with transfusion-dependent, low- and intermediate-risk myelodysplastic syndromes (MDS). The company also received a positive opinion from the European Medicines Agency (EMA) on its application for Orphan Drug Designation for amsulostat in the treatment of myelofibrosis. Additionally, Syntara presented clinical and preclinical data on amsulostat at the American Society of Hematology (ASH) Annual Meeting. The company's pipeline assets also progressed, with the SNT-4728 Phase 2 iRBD trial fully recruited and data expected in Q2 2026, and the topical anti-fibrotic SNT-9465 advancing into a Phase 1b hypertrophic scar study following successful completion of a Phase 1a study. Syntara also announced a collaboration with the Garvan Institute of Medical Research to evaluate amsulostat in a Phase 1/2 clinical trial for advanced pancreatic cancer, funded by the Australian Government's Medical Research Future Fund. The company reported a proforma cash balance of $12.3 million at the end of 2025.

Syntara expects five separate data read-outs across its clinical portfolio in 2026, each capable of materially advancing both value and strategic optionality.

2026 is shaping up to be a pivotal year for Syntara, with multiple data read-outs expected across the company's clinical portfolio, including in haematology, skin scarring, and neuroinflammation.